Search

Your search keyword '"Timmis, Adam D."' showing total 486 results
Start Over Author "Timmis, Adam D."
486 results on '"Timmis, Adam D."'

1. Health-related quality of life and healthcare costs of symptoms and cardiovascular disease events in patients with atrial fibrillation: a longitudinal analysis of 27 countries from the EURObservational Research Programme on Atrial Fibrillation general long-term registry

Author

Walli-Attaei, Marjan, Little, Mathew, Luengo-Fernandez, Ramon, Gray, Alastair, Torbica, Aleksandra, Maggioni, Aldo P, Bairami, Firoozeh, Huculeci, Radu, Aboyans, Victor, Timmis, Adam D, Vardas, Panos, and Leal, Jose

Abstract

Aims We examine the effects of symptoms and cardiovascular disease (CVD) events on health-related quality of life (HRQOL) and healthcare costs in a European population with atrial fibrillation (AF). Methods and results In the EURObservational Research Programme on AF long-term general registry, AF patients from 250 centres in 27 European countries were enrolled and followed for 2 years. We used fixed effects models to estimate the association of symptoms and CVD events on HRQOL and annual healthcare costs. We found significant decrements in HRQOL in AF patients in whom ST-segment elevation myocardial infarction (STEMI) [−0.075 (95% confidence interval −0.144, −0.006)], angina or non-ST-elevation myocardial infarction (NSTEMI) [−0.037 (−0.071, −0.003)], new-onset/worsening heart failure [−0.064 (−0.088, −0.039)], bleeding events [−0.031 (−0.059, −0.003)], thromboembolic events [−0.071 (−0.115, −0.027)], mild symptoms [0.037 (−0.048, −0.026)], or severe/disabling symptoms [−0.090 (−0.108, −0.072)] occurred during the follow-up. During follow-up, annual healthcare costs were associated with an increase of €11 718 (€8497, €14 939) in patients with STEMI, €5823 (€4757, €6889) in patients with angina/NSTEMI, €3689 (€3219, €4158) in patients with new-onset or worsening heart failure, €3792 (€3315, €4270) in patients with bleeding events, and €3182 (€2483, €3881) in patients with thromboembolic events, compared with AF patients without these events. Healthcare costs were primarily driven by inpatient costs. There were no significant differences in HRQOL or healthcare resource use between EU regions or by sex. Conclusion Symptoms and CVD events are associated with a high burden on AF patients and healthcare systems throughout Europe. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Guiding Therapy by Coronary CT Angiography Improves Outcomes in Patients With Stable Chest Pain

Author

Adamson, Philip D., Williams, Michelle C., Dweck, Marc R., Mills, Nicholas L., Boon, Nicholas A., Daghem, Marwa, Bing, Rong, Moss, Alastair J., Mangion, Kenneth, Flather, Marcus, Forbes, John, Hunter, Amanda, Norrie, John, Shah, Anoop S.V., Timmis, Adam D., van Beek, Edwin J.R., Ahmadi, Amir A., Leipsic, Jonathon, Narula, Jagat, Newby, David E., Roditi, Giles, McAllister, David A., and Berry, Colin

Published
2019
Full Text
View/download PDF

4. Routine use of fluoroscopic guidance and up-front femoral angiography results in reduced femoral complications in patients undergoing coronary angiographic procedures: an observational study using an Interrupted Time-Series analysis

Author

Castle, Emily V., Rathod, Krishnaraj S., Guttmann, Oliver P., Jenkins, Alice M., McCarthy, Carmel D., Knight, Charles J., O’Mahony, Constantinos, Mathur, Anthony, Smith, Elliot J., Weerackody, Roshan, Timmis, Adam D., Wragg, Andrew, and Jones, Daniel A.

Published
2019
Full Text
View/download PDF

7. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease

Author

Hageman, Steven H. J., McKay, Ailsa J., Ueda, Peter, Gunn, Laura H., Jernberg, Tomas, Hagström, Emil, Bhatt, Deepak L., Steg, Ph. Gabriel, Läll, Kristi, Mägi, Reedik, Gynnild, Mari Nordbø, Ellekjær, Hanne, Saltvedt, Ingvild, Tuñón, José, Mahíllo, Ignacio, Aceña, Álvaro, Kaminski, Karol, Chlabicz, Malgorzata, Sawicka, Emilia, Tillman, Taavi, McEvoy, John W., di Angelantonio, Emanuele, Graham, Ian, de Bacquer, Dirk, Ray, Kausik K., Dorresteijn, Jannick A. N., Visseren, Frank L. J., Asselbergs, F. W., Nathoe, H. M., de Borst, G. J., Bots, M. L., Geerlings, M. I., Emmelot, M. H., de Jong, P. A., Leiner, T., Lely, A. T., van der Kaaij, N. P., Kappelle, L. J., Ruigrok, Y. M., Verhaar, M. C., Visseren, F. L. J., Westerink, J., Halle, Martin, Timmis, Adam D., Lettino, Maddalena, Vardas, Panos E., McEvoy, John William, Graham, Ian M., and Academic Medical Center

Subjects
Cardiac & Cardiovascular Systems, PREDICTION, Myocardial Infarction, Residual risk, Risk Assessment, ARTERIAL-DISEASE, Recurrent risk, Risk Factors, Medicine and Health Sciences, Humans, Cardiac and Cardiovascular Systems, 1102 Cardiorespiratory Medicine and Haematology, METAANALYSIS, Science & Technology, Kardiologi, Secondary prevention, 1103 Clinical Sciences, ASSOCIATION, Atherosclerosis, Established ASCVD, COMPETING RISKS, PREVENTION, Risk prediction, Stroke, ASPIRIN, Cardiovascular System & Hematology, Cardiovascular Diseases, CLINICAL-PRACTICE, Personalized treatment, Cardiovascular System & Cardiology, Cardiology and Cardiovascular Medicine, OUTPATIENTS, Life Sciences & Biomedicine, Algorithms, Biomarkers, TASK-FORCE
Abstract

Aims The 10-year risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events in patients with established ASCVD can be estimated with the Secondary Manifestations of ARTerial disease (SMART) risk score, and may help refine clinical management. To broaden generalizability across regions, we updated the existing tool (SMART2 risk score) and recalibrated it with regional incidence rates and assessed its performance in external populations. Methods and results Individuals with coronary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysms were included from the Utrecht Cardiovascular Cohort-SMART cohort [n = 8355; 1706 ASCVD events during a median follow-up of 8.2 years (interquartile range 4.2-12.5)] to derive a 10-year risk prediction model for recurrent ASCVD events (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular mortality) using a Fine and Gray competing risk-adjusted model. The model was recalibrated to four regions across Europe, and to Asia (excluding Japan), Japan, Australia, North America, and Latin America using contemporary cohort data from each target region. External validation used data from seven cohorts [Clinical Practice Research Datalink, SWEDEHEART, the international REduction of Atherothrombosis for Continued Health (REACH) Registry, Estonian Biobank, Spanish Biomarkers in Acute Coronary Syndrome and Biomarkers in Acute Myocardial Infarction (BACS/BAMI), the Norwegian COgnitive Impairment After STroke, and Bialystok PLUS/Polaspire] and included 369 044 individuals with established ASCVD of whom 62 807 experienced an ASCVD event. C-statistics ranged from 0.605 [95% confidence interval (CI) 0.547-0.664] in BACS/BAMI to 0.772 (95% CI 0.659-0.886) in REACH Europe high-risk region. The clinical utility of the model was demonstrated across a range of clinically relevant treatment thresholds for intensified treatment options. Conclusion The SMART2 risk score provides an updated, validated tool for the prediction of recurrent ASCVD events in patients with established ASCVD across European and non-European populations. The use of this tool could allow for a more personalized approach to secondary prevention based upon quantitative rather than qualitative estimates of residual risk. Key objective To improve upon prediction of 10-year residual atherosclerotic cardiovascular disease (ASCVD) event risk in individuals with established ASCVD, by taking into account competing risks and geographical differences in ASCVD incidence. Key findings Derivation in 8355 individuals with established ASCVD from the Utrecht Cardiovascular Cohort-Secondary Manifestations of ARTerial disease (SMART) cohort. C-statistics ranged from 0.605 [95% confidence interval (CI) 0.547-0.664] to 0.772 (95% CI 0.659-0.886). Clinical utility was demonstrated across a range of treatment thresholds relevant to therapy intensification. Take-home messages The SMART2 risk score can be used to estimate 10-year residual risk of fatal and non-fatal ASCVD in individuals with established ASCVD. Adapted to the CVD incidence in several global regions. Facilitates shared decision-making on Step 2 prevention goals as recommended by the 2021 ESC Guidelines on cardiovascular prevention.

Published
2022
Full Text
View/download PDF

10. High-Sensitivity Cardiac Troponin I and the Diagnosis of Coronary Artery Disease in Patients With Suspected Angina Pectoris

Author

Adamson, Philip D., Hunter, Amanda, Madsen, Debbie M., Shah, Anoop S.V., McAllister, David A., Pawade, Tania A., Williams, Michelle C., Berry, Colin, Boon, Nicholas A., Flather, Marcus, Forbes, John, McLean, Scott, Roditi, Giles, Timmis, Adam D., van Beek, Edwin J.R., Dweck, Marc R., Mickley, Hans, Mills, Nicholas L., and Newby, David E.

Published
2018
Full Text
View/download PDF

11. Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial

Author

Adamson, Philip D, Hunter, Amanda, Williams, Michelle C, Shah, Anoop S V, McAllister, David A, Pawade, Tania A, Dweck, Marc R, Mills, Nicholas L, Berry, Colin, Boon, Nicholas A, Clark, Elizabeth, Flather, Marcus, Forbes, John, McLean, Scott, Roditi, Giles, van Beek, Edwin J R, Timmis, Adam D, and Newby, David E

Published
2018
Full Text
View/download PDF

21. Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort

Author

Hall, Marlous, Dondo, Tatendashe B., Yan, Andrew T., Mamas, Mamas A., Timmis, Adam D., Deanfield, John E., Jernberg, Tomas, Hemingway, Harry, Fox, Keith A. A., and Gale, Chris P.

Subjects
Heart attack -- Patient outcomes, Comorbidity -- Care and treatment -- Forecasts and trends -- Patient outcomes, Cardiac patients -- Care and treatment, Market trend/market analysis, Biological sciences
Abstract

Background There is limited knowledge of the scale and impact of multimorbidity for patients who have had an acute myocardial infarction (AMI). Therefore, this study aimed to determine the extent to which multimorbidity is associated with long-term survival following AMI. Methods and findings This national observational study included 693,388 patients (median age 70.7 years, 452,896 [65.5%] male) from the Myocardial Ischaemia National Audit Project (England and Wales) who were admitted with AMI between 1 January 2003 and 30 June 2013. There were 412,809 (59.5%) patients with multimorbidity at the time of admission with AMI, i.e., having at least 1 of the following long-term health conditions: diabetes, chronic obstructive pulmonary disease or asthma, heart failure, renal failure, cerebrovascular disease, peripheral vascular disease, or hypertension. Those with heart failure, renal failure, or cerebrovascular disease had the worst outcomes (39.5 [95% CI 39.0-40.0], 38.2 [27.7-26.8], and 26.6 [25.2-26.4] deaths per 100 person-years, respectively). Latent class analysis revealed 3 multimorbidity phenotype clusters: (1) a high multimorbidity class, with concomitant heart failure, peripheral vascular disease, and hypertension, (2) a medium multimorbidity class, with peripheral vascular disease and hypertension, and (3) a low multimorbidity class. Patients in class 1 were less likely to receive pharmacological therapies compared with class 2 and 3 patients (including aspirin, 83.8% versus 87.3% and 87.2%, respectively; [beta]-blockers, 74.0% versus 80.9% and 81.4%; and statins, 80.6% versus 85.9% and 85.2%). Flexible parametric survival modelling indicated that patients in class 1 and class 2 had a 2.4-fold (95% CI 2.3-2.5) and 1.5-fold (95% CI 1.4-1.5) increased risk of death and a loss in life expectancy of 2.89 and 1.52 years, respectively, compared with those in class 3 over the 8.4-year follow-up period. The study was limited to all-cause mortality due to the lack of available cause-specific mortality data. However, we isolated the disease-specific association with mortality by providing the loss in life expectancy following AMI according to multimorbidity phenotype cluster compared with the general age-, sex-, and year-matched population. Conclusions Multimorbidity among patients with AMI was common, and conferred an accumulative increased risk of death. Three multimorbidity phenotype clusters that were significantly associated with loss in life expectancy were identified and should be a concomitant treatment target to improve cardiovascular outcomes. Trial registration ClinicalTrials.gov NCT03037255., Author(s): Marlous Hall 1,*, Tatendashe B. Dondo 1, Andrew T. Yan 2, Mamas A. Mamas 3, Adam D. Timmis 4, John E. Deanfield 5, Tomas Jernberg 6, Harry Hemingway 7,8, [...]

Published
2018
Full Text
View/download PDF

25. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions

Author

Interne Geneeskunde Vasculaire, MS Interne Geneeskunde, Circulatory Health, MS Geriatrie, de Vries, Tamar, I, Cooney, Marie Therese, Selmer, Randi M., Hageman, Steven H. J., Pennells, Lisa A., Wood, Angela, Kaptoge, Stephen, Xu, Zhe, Westerink, Jan, Rabanal, Kjersti S., Tell, Grethe S., Meyer, Haakon E., Igland, Jannicke, Ariansen, Inger, Matsushita, Kunihiro, Blaha, Michael J., Nambi, Vijay, Peters, Ruth, Beckett, Nigel, Antikainen, Riitta, Bulpitt, Christopher J., Muller, Majon, Emmelot-Vonk, Marielle H., Trompet, Stella, Jukema, Wouter, Ference, Brian A., Halle, Martin, Timmis, Adam D., Vardas, Panos E., Dorresteijn, Jannick A. N., De Bacquer, Dirk, Di Angelantonio, Emanuele, Visseren, Frank L. J., Graham, Ian M., Interne Geneeskunde Vasculaire, MS Interne Geneeskunde, Circulatory Health, MS Geriatrie, de Vries, Tamar, I, Cooney, Marie Therese, Selmer, Randi M., Hageman, Steven H. J., Pennells, Lisa A., Wood, Angela, Kaptoge, Stephen, Xu, Zhe, Westerink, Jan, Rabanal, Kjersti S., Tell, Grethe S., Meyer, Haakon E., Igland, Jannicke, Ariansen, Inger, Matsushita, Kunihiro, Blaha, Michael J., Nambi, Vijay, Peters, Ruth, Beckett, Nigel, Antikainen, Riitta, Bulpitt, Christopher J., Muller, Majon, Emmelot-Vonk, Marielle H., Trompet, Stella, Jukema, Wouter, Ference, Brian A., Halle, Martin, Timmis, Adam D., Vardas, Panos E., Dorresteijn, Jannick A. N., De Bacquer, Dirk, Di Angelantonio, Emanuele, Visseren, Frank L. J., and Graham, Ian M.

Published
2021

30. Long-term Survival in Patients Undergoing Percutaneous Interventions With or Without Intracoronary Pressure Wire Guidance or Intracoronary Ultrasonographic Imaging: A Large Cohort Study

Author

Fröhlich, Georg M., Redwood, Simon, Rakhit, Roby, MacCarthy, Philip A., Lim, Pitt, Crake, Tom, White, Steven K., Knight, Charles J., Kustosz, Christoph, Knapp, Guido, Dalby, Miles C., Mali, Iqbal S., Archbold, Andrew, Wragg, Andrew, Timmis, Adam D., and Meier, Pascal

Published
2014
Full Text
View/download PDF

31. Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients

Author

Archbold, R. Andrew, Balami, Dauda, Al-Hajiri, Abdul, Suliman, Abdel, Liew, Reg, Cooper, Jackie, Ranjadayalan, Kulasegarum, Knight, Charles J., Deaner, Andrew, and Timmis, Adam D.

Subjects
Hemoglobin -- Analysis, Heart failure -- Risk factors, Coronary heart disease -- Patient outcomes, Coronary heart disease -- Research, Anemia -- Research, Health
Published
2006

33. Contributors

Author

Ali, F. Runa, primary, Archbold, Andrew, additional, Cerio, Rino, additional, Chowdhury, Tahseen A., additional, Coombes, Andrew, additional, D’Cruz, David P., additional, Drake, William M., additional, Feather, Adam, additional, Gallagher, Jayne, additional, Glynn, Michael, additional, Ghosh, Robert, additional, Goh, Beng T., additional, Monson, John P., additional, Moore-Gillon, John C., additional, Naftalin, Alan, additional, Nikolic, Serge, additional, Riddell, Anna, additional, Taylor, Ruth E., additional, Timmis, Adam D., additional, Thuraisingham, Raj, additional, Walker, Rodney W.H., additional, and Wareing, Michael P., additional

Published
2012
Full Text
View/download PDF

34. Clinical outcomes after myocardial revascularization according to operator training status: cohort study of 22 697 patients undergoing percutaneous coronary intervention or coronary artery bypass graft surgery

Author

Jones, Daniel A., Gallagher, Sean, Rathod, Krishnaraj, Jain, Ajay K., Mathur, Anthony, Uppal, Rakesh, Westwood, Mark, Wong, Kit, Rothman, Martin T., Shipolini, Alex, Smith, Elliot J., Mills, Peter G., Timmis, Adam D., Knight, Charles J., Archbold, R. Andrew, and Wragg, Andrew

Published
2013
Full Text
View/download PDF

38. Safety and feasibility of hospital discharge 2 days following primary percutaneous intervention for ST-segment elevation myocardial infarction

Author

Jones, Daniel A, Rathod, Krishnaraj S, Howard, James Philip, Gallagher, Sean, Antoniou, Sotiris, De Palma, Rodney, Guttmann, Oliver, Cliffe, Samantha, Colley, Judith, Butler, Jane, Ferguson, Eileen, Mohiddin, Saidi, Kapur, Akhil, Knight, Charles J, Jain, Ajay K, Rothman, Martin T, Mathur, Anthony, Timmis, Adam D, Smith, Elliot J, and Wragg, Andrew

Published
2012
Full Text
View/download PDF

40. Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization

Author

Hemingway, Harry, Crook, Angela M., Feder, Gene, Banerjee, Shrilla, Dawson, J. Rex, Magee, Patrick, Philpott, Sue, Sanders, Julie, Wood, Alan, and Timmis, Adam D.

Subjects
Coronary heart disease -- Care and treatment, Transluminal angioplasty -- Health aspects, Coronary artery bypass -- Health aspects, Decision support systems -- Evaluation
Abstract

Many patients with coronary artery disease who would benefit from angioplasty or bypass surgery are not receiving it. Of 2,261 patients who would have benefited from angioplasty or bypass surgery, one-third were treated with drugs instead. These patients were more likely to have chest pain, a heart attack, or die than those who received angioplasty or bypass surgery.

Published
2001

43. Sex associations and computed tomography coronary angiography-guided management in patients with stable chest pain

Author

Mangion, Kenneth, primary, Adamson, Philip D, additional, Williams, Michelle C, additional, Hunter, Amanda, additional, Pawade, Tania, additional, Shah, Anoop S V, additional, Lewis, Stephanie, additional, Boon, Nicholas A, additional, Flather, Marcus, additional, Forbes, John, additional, McLean, Scott, additional, Roditi, Giles, additional, van Beek, Edwin J R, additional, Timmis, Adam D, additional, Newby, David E, additional, McAllister, David A, additional, and Berry, Colin, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results